Last reviewed · How we verify
NCT04281459
Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction
NA trial testing HIV Treatment Satisfaction Questionnaire status in HIV-1-infection in 33 participants. Completed in 30 November 2020.
1 June 2020
Quick facts
| Lead sponsor | Azienda Ospedaliera Universitaria Integrata Verona |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 33 |
| Start date | 1 March 2020 |
| Primary completion | 1 June 2020 |
| Estimated completion | 30 November 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- HIV Treatment Satisfaction Questionnaire status
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona — full company profile →
Who can join
Adults 18 to 65, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With this study the investigators propose to evaluate the satisfaction of the patients receiving antiretroviral treatment for HIV infection with standard everyday scheme, compared to patients receiving the same treatment with short-cycles of 4 days a week.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04281459
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other Azienda Ospedaliera Universitaria Integrata Verona trials
Trials by the same sponsor.
- NCT07325877 — Supra-papillary Versus Trans-papillary Biliary Stenting in Malignant Peri-hilar Stenosis · NA · not yet recruiting
- NCT07289035 — Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. · Phase 2 · not yet recruiting
- NCT07186582 — Verona Coronary Physiology Interventional Registry · active not recruiting
- NCT06820541 — Gallbladder Stenting in FC-SEMS · NA · not yet recruiting
- NCT07338708 — Visual Outcomes and Quality of Life After Vivity EDOF IOL Implantation in Early-Stage Keratoconus · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04281459 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Universitaria Integrata Verona
- Last refreshed: 30 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04281459.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing